View source for Document:EU GVP: Module XVI EMA/204715/2012 Rev. 3 (2024)

<noinclude>{{#set:
|DocReference=EU  GVP: Module XVI
EMA/204715/2012  Rev. 3 (2024)
|DocValidityArea=EU
|DocScopes=G
|DocName=GVP: Module XVI
EMA/204715/2012
|DocVersion=Rev. 3 (2024)
|DocStatus=Current
|DocType=Official guideline
|DocLanguage=EN
|DocDescription=Guideline on good pharmacovigilance practices (GVP)
Module XVI – Risk minimisation measures (Rev 3)

(Including NIS)
|DocRestricted=No
|DocSubmittedBy=Florian Adragna
|DocContributors=
}}</noinclude>

{{DocumentBox
|reference=EU  GVP: Module XVI
EMA/204715/2012  Rev. 3 (2024)
|validity_area=EU
|scopes=G
|doc_name=GVP: Module XVI
EMA/204715/2012
|version=Rev. 3 (2024)
|status=Current
|doc_type=Official guideline
|language=EN
|description=Guideline on good pharmacovigilance practices (GVP)
Module XVI – Risk minimisation measures (Rev 3)

(Including NIS)
|official_link=https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-xvi-risk-minimisation-measures-rev-3_en.pdf
|restricted=No
|submitted_by=Florian Adragna
|contributors=
}}